For instance, treatment of chemo-resistant chronic myeloid leukemia cells with a BCR-ABL tyrosine kinase inhibitor demonstrated that increase in ceramide synthases preceded cell death36. Here, TLCD3B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.